+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
mRNA CDMO Service Market - Global Forecast 2026-2032- Product Image
mRNA CDMO Service Market - Global Forecast 2026-2032- Product Image
Sale

mRNA CDMO Service Market - Global Forecast 2026-2032

  • Report

  • 183 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6148453
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The mRNA CDMO Service Market is projected to reach USD 5.92 Billion in 2026. It is expected to continue growing at a CAGR of 7.32%, reaching USD 9.01 Billion by 2032.

mRNA CDMO Services: Executive Overview

mRNA contract development and manufacturing organization (CDMO) services support the design, process development, analytical characterization, scale-up, and manufacture of messenger RNA products. The market is shaped by demand for flexible, quality-focused production capabilities spanning research, preclinical, clinical, and commercial requirements. Service differentiation increasingly depends on integrated workflows, reproducible processes, regulatory readiness, and the ability to manage specialized raw materials and delivery systems.

How mRNA Manufacturing Is Reshaping Biopharma Operations

mRNA manufacturing is moving from narrowly focused vaccine production toward broader therapeutic and preventive applications. This shift is increasing the importance of platform technologies that can be adapted across sequences, formulations, and dosage requirements. CDMOs are also being evaluated on their ability to connect formulation, lipid nanoparticle development, process analytics, fill-finish coordination, and technology transfer within a controlled quality system.

Operational priorities are changing accordingly. Sponsors increasingly seek shorter development cycles, transparent batch documentation, robust supply-chain controls, and production models that can accommodate smaller or variable batch requirements. These needs favor providers with modular facilities, experienced technical teams, and validated analytical methods rather than capacity alone.

Artificial Intelligence Strengthens mRNA CDMO Decision-Making

Artificial intelligence can improve mRNA CDMO activities by supporting sequence design, formulation screening, process parameter optimization, deviation analysis, and predictive maintenance. Machine-learning tools may help identify relationships among raw-material attributes, reaction conditions, purification performance, encapsulation behavior, and product quality, provided that training data are reliable and model outputs remain scientifically interpretable.

The cumulative impact is likely to be greatest when AI is integrated with laboratory automation, electronic batch records, process analytical technology, and quality systems. Adoption still requires data governance, cybersecurity, model validation, change control, and human oversight. AI should therefore be treated as an augmenting capability that supports technical judgment and compliance, not as a replacement for validated manufacturing procedures.

Regional Dynamics Across the mRNA CDMO Services Landscape

North America combines advanced biotechnology ecosystems, substantial clinical-development activity, and mature regulatory and manufacturing infrastructure. Europe benefits from strong pharmaceutical research capabilities and coordinated quality expectations, while national differences in funding, permitting, and production specialization remain relevant. Asia-Pacific includes highly active research and manufacturing centers, with growing attention to technology transfer, regional resilience, and domestic biopharmaceutical capabilities.

Latin America is developing mRNA-related capabilities through public-health programs, academic research, and partnerships, although access to specialized equipment, technical talent, and qualified inputs can vary. The Middle East is emphasizing biotechnology diversification and localized health-security capacity, while Africa’s opportunity is closely linked to technology access, workforce development, and sustainable manufacturing partnerships. Across all regions, regulatory alignment and dependable cold-chain and raw-material networks remain important enabling conditions.

Group Insights: ASEAN, BRICS, EU, G7, GCC, and NATO

ASEAN presents a diverse combination of manufacturing, research, and public-health priorities, making cross-border regulatory coordination and workforce development important for regional capability building. BRICS members span substantial scientific and industrial resources but differ in regulatory systems, infrastructure, and access to specialized inputs, creating both collaboration opportunities and execution complexity.

The European Union emphasizes harmonized quality and regulatory frameworks alongside distributed national capabilities. G7 economies generally combine strong research ecosystems with advanced quality, automation, and biologics-manufacturing expertise. GCC countries are investing in biotechnology and health-security infrastructure, with partnerships and talent development central to execution. NATO members bring extensive biomedical and supply-chain capabilities, while resilience planning and secure access to critical materials are increasingly relevant to strategic manufacturing discussions.

Country-Level Considerations for mRNA CDMO Engagement

Australia, Canada, France, Germany, Italy, Spain, the United Kingdom, and the United States offer established research, clinical, regulatory, or biomanufacturing capabilities, though specialization and regional concentration differ. These countries are well positioned for integrated development services, advanced analytics, and collaboration between public research organizations and private manufacturers.

Brazil, Mexico, India, China, Japan, South Korea, and Russia reflect varied combinations of domestic health priorities, technical capacity, manufacturing infrastructure, and regulatory development. China, Japan, South Korea, and India have particularly important roles in Asian biopharmaceutical development and production networks, while Brazil and Mexico are relevant to Latin American capability building. Country selection should consider quality-system maturity, technology-transfer experience, local regulatory pathways, supply continuity, and the availability of appropriately trained personnel rather than geography alone.

Priorities for Leaders Selecting and Scaling mRNA CDMO Partnerships

Industry leaders should define a target product profile and stage-appropriate manufacturing plan before selecting a CDMO. Evaluation should cover sequence and construct development, enzymatic synthesis, purification, lipid nanoparticle formulation, analytical release testing, stability programs, aseptic operations, documentation, and technology-transfer responsibilities. Quality agreements should clearly assign ownership for deviations, investigations, change control, data integrity, and regulatory submissions.

Sponsors should also test operational resilience through supplier qualification, dual sourcing where practical, contingency planning, and realistic scale-up exercises. A staged engagement model can reduce execution risk by linking technical milestones to progression decisions. Finally, leaders should assess AI and automation capabilities through evidence of validated use, traceable data, cybersecurity controls, and measurable improvements in reproducibility or cycle time.

Research Methodology for the mRNA CDMO Services Assessment

This executive summary uses a structured market-analysis approach centered on the scope of mRNA CDMO services. The assessment organizes insights across service workflows, manufacturing requirements, technology shifts, regulatory considerations, regional conditions, country capabilities, and strategic priorities. It distinguishes established operational practices from emerging opportunities and considers the implications of specialized inputs, analytical control, delivery-system development, and technology transfer.

The analysis is qualitative and evidence-led. It does not provide market estimates, market sizing, market shares, or forecasts. Regional, group, and country observations are framed as comparative considerations requiring validation against current regulatory guidance, facility status, supplier qualification records, clinical-development needs, and publicly available technical evidence before investment or procurement decisions are made.

Conclusion: Building Reliable, Flexible mRNA Manufacturing Networks

mRNA CDMO services are becoming a strategic component of biopharmaceutical development and manufacturing, with value increasingly tied to integrated technical execution, quality assurance, analytical depth, and supply-chain resilience. Regional and country capabilities vary, so sponsors must match service requirements with demonstrated expertise, regulatory readiness, and fit-for-purpose infrastructure.

The strongest operating models will combine flexible manufacturing platforms with disciplined process control, transparent data practices, and carefully governed use of artificial intelligence. Leaders that prioritize qualified partnerships, robust technology transfer, resilient sourcing, and evidence-based scale-up will be better positioned to advance mRNA programs while managing technical and compliance risk.

This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. mRNA CDMO Service Market, by Service Type
7.1. Introduction
7.2. Analytical Services
7.2.1. Bioanalytical Testing
7.2.2. Physical Chemical Characterization
7.2.3. Stability Studies
7.3. Formulation & Fill-Finish
7.3.1. Liquid Formulation
7.3.2. Lyophilized Formulation
7.4. Manufacturing Services
7.4.1. Commercial Manufacturing
7.4.2. Research And Development Manufacturing
7.5. Process Development
7.5.1. Downstream Process Development
7.5.2. Upstream Process Development
7.6. Quality Control & Assurance
7.6.1. Quality Control Testing
7.6.2. Regulatory Affairs Support
8. mRNA CDMO Service Market, by Application
8.1. Introduction
8.2. Diagnostics
8.3. Therapeutics
8.4. Vaccines
8.4.1. Cancer Vaccines
8.4.1.1. Prophylactic Cancer Vaccines
8.4.1.2. Therapeutic Cancer Vaccines
8.4.2. Infectious Disease Vaccines
8.4.2.1. Covid-19 Vaccines
8.4.2.2. Influenza Vaccines
9. mRNA CDMO Service Market, by End Users
9.1. Introduction
9.2. Biotechnology Companies
9.3. Contract Research Organizations
9.4. Pharmaceutical Companies
9.5. Research Institutes
10. mRNA CDMO Service Market, by Technology Platform
10.1. Introduction
10.2. Lipid Nanoparticle
10.2.1. Cationic Lipid Nanoparticle
10.2.2. Ionizable Lipid Nanoparticle
10.3. Polymer-Based Systems
10.4. Viral Vector
10.4.1. AAV Vector
10.4.2. Adenovirus Vector
10.4.3. Lentivirus Vector
11. mRNA CDMO Service Market, by Scale
11.1. Introduction
11.2. Clinical Scale
11.3. Commercial Scale
11.4. Pilot Scale
11.5. Small Scale
12. mRNA CDMO Service Market, by Region
12.1. Introduction
12.2. Asia-Pacific
12.3. North America
12.4. Latin America
12.5. Europe
12.6. Middle East
12.7. Africa
13. mRNA CDMO Service Market, by Group
13.1. Introduction
13.2. ASEAN
13.3. GCC
13.4. European Union
13.5. BRICS
13.6. G7
13.7. NATO
14. mRNA CDMO Service Market, by Country
14.1. Introduction
14.2. United States
14.3. Canada
14.4. Mexico
14.5. Brazil
14.6. United Kingdom
14.7. Germany
14.8. France
14.9. Russia
14.10. Italy
14.11. Spain
14.12. China
14.13. India
14.14. Japan
14.15. Australia
14.16. South Korea
15. Competitive Landscape
15.1. Market Share Analysis, 2025
15.2. Market Concentration Analysis, 2025
15.2.1. Concentration Ratio (CR)
15.2.2. Herfindahl Hirschman Index (HHI)
15.3. Recent Developments & Impact Analysis, 2025
15.4. Product Portfolio Analysis, 2025
15.5. Benchmarking Analysis, 2025
16. Company Profiles
16.1. AGC Biologics Inc.
16.2. Boehringer Ingelheim International GmbH
16.3. Catalent, Inc.
16.4. CordenPharma
16.5. Danaher company
16.6. Evonik Industries AG
16.7. FUJIFILM Diosynth Biotechnologies UK Limited
16.8. Lonza Group Ltd
16.9. Merck KGaA
16.10. Recipharm AB
16.11. Samsung Biologics Co., Ltd.
16.12. Thermo Fisher Scientific Inc.
16.13. TriLink BioTechnologies
16.14. WuXi Biologics (Cayman) Inc.
17. Key Experts
LIST OF FIGURES
FIGURE 1. Global mRNA CDMO Service Market, Years Considered for the Study
FIGURE 2. Global mRNA CDMO Service Market, Research Design
FIGURE 3. Global mRNA CDMO Service Market, Research Framework
FIGURE 4. Global mRNA CDMO Service Market, Data Triangulation
FIGURE 5. Global mRNA CDMO Service Market Size, 2017-2032 (USD Million)
FIGURE 6. Global mRNA CDMO Service Market Size, by Service Type, 2025 vs 2032 (%)
FIGURE 7. Global mRNA CDMO Service Market Size, by Service Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global mRNA CDMO Service Market Size, by Application, 2025 vs 2032 (%)
FIGURE 9. Global mRNA CDMO Service Market Size, by Application, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global mRNA CDMO Service Market Size, by End Users, 2025 vs 2032 (%)
FIGURE 11. Global mRNA CDMO Service Market Size, by End Users, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global mRNA CDMO Service Market Size, by Technology Platform, 2025 vs 2032 (%)
FIGURE 13. Global mRNA CDMO Service Market Size, by Technology Platform, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global mRNA CDMO Service Market Size, by Scale, 2025 vs 2032 (%)
FIGURE 15. Global mRNA CDMO Service Market Size, by Scale, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global mRNA CDMO Service Market Size, by Region, 2025 vs 2032 (%)
FIGURE 17. Global mRNA CDMO Service Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global mRNA CDMO Service Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 19. Global mRNA CDMO Service Market Size, by Country, 2025 vs 2032 (%)
FIGURE 20. Global mRNA CDMO Service Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 21. Global mRNA CDMO Service Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global mRNA CDMO Service Market Segmentation & Coverage
TABLE 2. Global mRNA CDMO Service Market Size, 2017-2032 (USD Million)
TABLE 3. Global mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 4. Global Analytical Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Analytical Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Analytical Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Bioanalytical Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Bioanalytical Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Bioanalytical Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Physical Chemical Characterization Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Physical Chemical Characterization Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Physical Chemical Characterization Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Stability Studies Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Stability Studies Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Stability Studies Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Formulation & Fill-Finish Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Formulation & Fill-Finish Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Formulation & Fill-Finish Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Liquid Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Liquid Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Liquid Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Lyophilized Formulation Market Size, by Region, 2017-2032 (USD Million)
TABLE 23. Global Lyophilized Formulation Market Size, by Group, 2017-2032 (USD Million)
TABLE 24. Global Lyophilized Formulation Market Size, by Country, 2017-2032 (USD Million)
TABLE 25. Global Manufacturing Services Market Size, by Region, 2017-2032 (USD Million)
TABLE 26. Global Manufacturing Services Market Size, by Group, 2017-2032 (USD Million)
TABLE 27. Global Manufacturing Services Market Size, by Country, 2017-2032 (USD Million)
TABLE 28. Global Commercial Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 29. Global Commercial Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 30. Global Commercial Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 31. Global Research And Development Manufacturing Market Size, by Region, 2017-2032 (USD Million)
TABLE 32. Global Research And Development Manufacturing Market Size, by Group, 2017-2032 (USD Million)
TABLE 33. Global Research And Development Manufacturing Market Size, by Country, 2017-2032 (USD Million)
TABLE 34. Global Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 35. Global Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 36. Global Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 37. Global Downstream Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 38. Global Downstream Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 39. Global Downstream Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 40. Global Upstream Process Development Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Upstream Process Development Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Upstream Process Development Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Quality Control & Assurance Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Quality Control & Assurance Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Quality Control & Assurance Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Quality Control Testing Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Quality Control Testing Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Quality Control Testing Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Regulatory Affairs Support Market Size, by Region, 2017-2032 (USD Million)
TABLE 50. Global Regulatory Affairs Support Market Size, by Group, 2017-2032 (USD Million)
TABLE 51. Global Regulatory Affairs Support Market Size, by Country, 2017-2032 (USD Million)
TABLE 52. Global mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 53. Global Diagnostics Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Diagnostics Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Diagnostics Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Therapeutics Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Therapeutics Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Therapeutics Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 63. Global Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 64. Global Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 65. Global Prophylactic Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 66. Global Prophylactic Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 67. Global Prophylactic Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 68. Global Therapeutic Cancer Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 69. Global Therapeutic Cancer Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 70. Global Therapeutic Cancer Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 71. Global Infectious Disease Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 72. Global Infectious Disease Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 73. Global Infectious Disease Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 74. Global Covid-19 Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 75. Global Covid-19 Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 76. Global Covid-19 Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 77. Global Influenza Vaccines Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Global Influenza Vaccines Market Size, by Group, 2017-2032 (USD Million)
TABLE 79. Global Influenza Vaccines Market Size, by Country, 2017-2032 (USD Million)
TABLE 80. Global mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 81. Global Biotechnology Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 82. Global Biotechnology Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 83. Global Biotechnology Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 84. Global Contract Research Organizations Market Size, by Region, 2017-2032 (USD Million)
TABLE 85. Global Contract Research Organizations Market Size, by Group, 2017-2032 (USD Million)
TABLE 86. Global Contract Research Organizations Market Size, by Country, 2017-2032 (USD Million)
TABLE 87. Global Pharmaceutical Companies Market Size, by Region, 2017-2032 (USD Million)
TABLE 88. Global Pharmaceutical Companies Market Size, by Group, 2017-2032 (USD Million)
TABLE 89. Global Pharmaceutical Companies Market Size, by Country, 2017-2032 (USD Million)
TABLE 90. Global Research Institutes Market Size, by Region, 2017-2032 (USD Million)
TABLE 91. Global Research Institutes Market Size, by Group, 2017-2032 (USD Million)
TABLE 92. Global Research Institutes Market Size, by Country, 2017-2032 (USD Million)
TABLE 93. Global mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 94. Global Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
TABLE 95. Global Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
TABLE 96. Global Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
TABLE 97. Global Cationic Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
TABLE 98. Global Cationic Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
TABLE 99. Global Cationic Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
TABLE 100. Global Ionizable Lipid Nanoparticle Market Size, by Region, 2017-2032 (USD Million)
TABLE 101. Global Ionizable Lipid Nanoparticle Market Size, by Group, 2017-2032 (USD Million)
TABLE 102. Global Ionizable Lipid Nanoparticle Market Size, by Country, 2017-2032 (USD Million)
TABLE 103. Global Polymer-Based Systems Market Size, by Region, 2017-2032 (USD Million)
TABLE 104. Global Polymer-Based Systems Market Size, by Group, 2017-2032 (USD Million)
TABLE 105. Global Polymer-Based Systems Market Size, by Country, 2017-2032 (USD Million)
TABLE 106. Global Viral Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 107. Global Viral Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 108. Global Viral Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 109. Global AAV Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 110. Global AAV Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 111. Global AAV Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 112. Global Adenovirus Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 113. Global Adenovirus Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 114. Global Adenovirus Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 115. Global Lentivirus Vector Market Size, by Region, 2017-2032 (USD Million)
TABLE 116. Global Lentivirus Vector Market Size, by Group, 2017-2032 (USD Million)
TABLE 117. Global Lentivirus Vector Market Size, by Country, 2017-2032 (USD Million)
TABLE 118. Global mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 119. Global Clinical Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 120. Global Clinical Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 121. Global Clinical Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 122. Global Commercial Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 123. Global Commercial Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 124. Global Commercial Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 125. Global Pilot Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 126. Global Pilot Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 127. Global Pilot Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 128. Global Small Scale Market Size, by Region, 2017-2032 (USD Million)
TABLE 129. Global Small Scale Market Size, by Group, 2017-2032 (USD Million)
TABLE 130. Global Small Scale Market Size, by Country, 2017-2032 (USD Million)
TABLE 131. Global mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 132. Asia-Pacific mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Asia-Pacific mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 134. Asia-Pacific mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 135. Asia-Pacific mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 136. Asia-Pacific mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 137. Asia-Pacific mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 138. Asia-Pacific mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 139. Asia-Pacific mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 140. Asia-Pacific mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 141. Asia-Pacific mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 142. Asia-Pacific mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 143. Asia-Pacific mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 144. Asia-Pacific mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 145. Asia-Pacific mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 146. Asia-Pacific mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 147. Asia-Pacific mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 148. North America mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 149. North America mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 150. North America mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 151. North America mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 152. North America mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 153. North America mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 154. North America mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 155. North America mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 156. North America mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 157. North America mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 158. North America mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 159. North America mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 160. North America mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 161. North America mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 162. North America mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 163. North America mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 164. Latin America mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 165. Latin America mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 166. Latin America mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 167. Latin America mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 168. Latin America mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 169. Latin America mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 170. Latin America mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 171. Latin America mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 172. Latin America mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 173. Latin America mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 174. Latin America mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 175. Latin America mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 176. Latin America mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 177. Latin America mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 178. Latin America mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 179. Latin America mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 180. Europe mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 181. Europe mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 182. Europe mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 183. Europe mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 184. Europe mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 185. Europe mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 186. Europe mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 187. Europe mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 188. Europe mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 189. Europe mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 190. Europe mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 191. Europe mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 192. Europe mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 193. Europe mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 194. Europe mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 195. Europe mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 196. Middle East mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 197. Middle East mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 198. Middle East mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 199. Middle East mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 200. Middle East mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 201. Middle East mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 202. Middle East mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 203. Middle East mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 204. Middle East mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 205. Middle East mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 206. Middle East mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 207. Middle East mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 208. Middle East mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 209. Middle East mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 210. Middle East mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 211. Middle East mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 212. Africa mRNA CDMO Service Market Size, by Region, 2017-2032 (USD Million)
TABLE 213. Africa mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 214. Africa mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 215. Africa mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 216. Africa mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 217. Africa mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 218. Africa mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 219. Africa mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 220. Africa mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 221. Africa mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 222. Africa mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 223. Africa mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 224. Africa mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 225. Africa mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 226. Africa mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 227. Africa mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 228. Global mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 229. ASEAN mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 230. ASEAN mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 231. ASEAN mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 232. ASEAN mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 233. ASEAN mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 234. ASEAN mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 235. ASEAN mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 236. ASEAN mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 237. ASEAN mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 238. ASEAN mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 239. ASEAN mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 240. ASEAN mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 241. ASEAN mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 242. ASEAN mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 243. ASEAN mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 244. ASEAN mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 245. GCC mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 246. GCC mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 247. GCC mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 248. GCC mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 249. GCC mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 250. GCC mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 251. GCC mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 252. GCC mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 253. GCC mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 254. GCC mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 255. GCC mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 256. GCC mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 257. GCC mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 258. GCC mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 259. GCC mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 260. GCC mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 261. European Union mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 262. European Union mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 263. European Union mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 264. European Union mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 265. European Union mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 266. European Union mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 267. European Union mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 268. European Union mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 269. European Union mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 270. European Union mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 271. European Union mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 272. European Union mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 273. European Union mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 274. European Union mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 275. European Union mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 276. European Union mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 277. BRICS mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 278. BRICS mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 279. BRICS mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 280. BRICS mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 281. BRICS mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 282. BRICS mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 283. BRICS mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 284. BRICS mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 285. BRICS mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 286. BRICS mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 287. BRICS mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 288. BRICS mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 289. BRICS mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 290. BRICS mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 291. BRICS mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 292. BRICS mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 293. G7 mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 294. G7 mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 295. G7 mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 296. G7 mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 297. G7 mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 298. G7 mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 299. G7 mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 300. G7 mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 301. G7 mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 302. G7 mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 303. G7 mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 304. G7 mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 305. G7 mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 306. G7 mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 307. G7 mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 308. G7 mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 309. NATO mRNA CDMO Service Market Size, by Group, 2017-2032 (USD Million)
TABLE 310. NATO mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 311. NATO mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 312. NATO mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 313. NATO mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 314. NATO mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 315. NATO mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 316. NATO mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 317. NATO mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 318. NATO mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 319. NATO mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 320. NATO mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 321. NATO mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 322. NATO mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 323. NATO mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 324. NATO mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 325. Global mRNA CDMO Service Market Size, by Country, 2017-2032 (USD Million)
TABLE 326. United States mRNA CDMO Service Market Size, 2017-2032 (USD Million)
TABLE 327. United States mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 328. United States mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 329. United States mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 330. United States mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 331. United States mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 332. United States mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 333. United States mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 334. United States mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 335. United States mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 336. United States mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 337. United States mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 338. United States mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 339. United States mRNA CDMO Service Market Size, by Lipid Nanoparticle, 2017-2032 (USD Million)
TABLE 340. United States mRNA CDMO Service Market Size, by Viral Vector, 2017-2032 (USD Million)
TABLE 341. United States mRNA CDMO Service Market Size, by Scale, 2017-2032 (USD Million)
TABLE 342. Canada mRNA CDMO Service Market Size, 2017-2032 (USD Million)
TABLE 343. Canada mRNA CDMO Service Market Size, by Service Type, 2017-2032 (USD Million)
TABLE 344. Canada mRNA CDMO Service Market Size, by Analytical Services, 2017-2032 (USD Million)
TABLE 345. Canada mRNA CDMO Service Market Size, by Formulation & Fill-Finish, 2017-2032 (USD Million)
TABLE 346. Canada mRNA CDMO Service Market Size, by Manufacturing Services, 2017-2032 (USD Million)
TABLE 347. Canada mRNA CDMO Service Market Size, by Process Development, 2017-2032 (USD Million)
TABLE 348. Canada mRNA CDMO Service Market Size, by Quality Control & Assurance, 2017-2032 (USD Million)
TABLE 349. Canada mRNA CDMO Service Market Size, by Application, 2017-2032 (USD Million)
TABLE 350. Canada mRNA CDMO Service Market Size, by Vaccines, 2017-2032 (USD Million)
TABLE 351. Canada mRNA CDMO Service Market Size, by Cancer Vaccines, 2017-2032 (USD Million)
TABLE 352. Canada mRNA CDMO Service Market Size, by Infectious Disease Vaccines, 2017-2032 (USD Million)
TABLE 353. Canada mRNA CDMO Service Market Size, by End Users, 2017-2032 (USD Million)
TABLE 354. Canada mRNA CDMO Service Market Size, by Technology Platform, 2017-2032 (USD Million)
TABLE 355. Canada mRNA CDMO Ser

Companies Mentioned

  • AGC Biologics Inc.
  • Boehringer Ingelheim International GmbH
  • Catalent, Inc.
  • CordenPharma
  • Danaher company
  • Evonik Industries AG
  • FUJIFILM Diosynth Biotechnologies UK Limited
  • Lonza Group Ltd
  • Merck KGaA
  • Recipharm AB
  • Samsung Biologics Co., Ltd.
  • Thermo Fisher Scientific Inc.
  • TriLink BioTechnologies
  • WuXi Biologics (Cayman) Inc.

Related Topics

Related Reports

Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026 - Product Image

Messenger Ribo Nucleic Acid (mRNA) Vaccine Contract Development and Manufacturing Organization (CDMO) Market Report 2026

  • Report
  • 250 Pages
  • Global
From
mRNA Therapeutics CDMO Market Report 2026 - Product Image

mRNA Therapeutics CDMO Market Report 2026

  • Report
  • 250 Pages
  • Global
From
mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031 - Product Image

mRNA Therapeutics Contract Development & Manufacturing (CDMO) Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2021-2031

  • Report
  • 185 Pages
  • Global
From
Lipid Nanoparticle CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Lipid Nanoparticle CDMO - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 180 Pages
  • Global
From
Lipid Nanoparticle CDMO Market Report: Trends, Forecast and Competitive Analysis to 2031 - Product Image

Lipid Nanoparticle CDMO Market Report: Trends, Forecast and Competitive Analysis to 2031

  • Report
  • 176 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.